Myf5-Cre

Nomenclature

C57BL/6Smoc-Myf5em1(Cre-WPRE-polyA)Smoc

Cat. NO.

NM-KI-200147

Strain State

Sperm cryopreservation

Export PDF

Gene Summary

Gene Symbol
Myf5

Synonyms

Myf-5; bHLHc2; B130010J22Rik

Chromosome

10

NCBI ID

17877

MGI ID

97252

Ensembl ID

ENSMUSG00000000435

Pubmed

Myf5

Human Ortholog

MYF5

Model Description

A Cre-WPRE-polyA expression cassette was knocked into the Myf5 gene start codon site. Myogenic factor 5 (Myf5) belongs to the MRF family transcription factors that regulate myogenesis. It is expressed in the skeletal muscle and satellite cells. Severe loss of skeletal muscle following ablation of Myf5-expressing progenitors. This strain is useful in studying the differentiation of skeletal muscle.
Research Application：Cre recombinase tool

Validation Data

image.png

Fig. 1 Cre-mediated recombination in the skeletal muscle of Myf5Cre/+; Rosa26tdTomato/+ mouse. TdTomato(red) expression can be detected in the muscle cells of Myf5Cre/+; Rosa26tdTomato/+ mouse.

image.png

Fig. 2 Detection of tdTomato(red) in various tissues of Myf5Cre/+; Rosa26tdTomato/+ mice. Tdtomato was expressed in the skeletal muscle. TdTomato can also be detected in individual cells of the brain, pituitary gland, eyes, salivary gland, heart, liver, spleen, lung, kidney, colon, intestine, stomach, pancreas, reproductive system and skin. (For more detailed information please contact our technical advisor.)


You may also like

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more
Workshop：Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

Learn more